- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05281601
AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics (TRUST)
Open-Label, Uncontrolled, Single Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged ≥ 29 Weeks Gestational Age to < 18 Years
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium, 3000
- Research Site
-
-
-
-
-
Belo Horizonte, Brazil, 30130-100
- Research Site
-
Porto Alegre, Brazil, 90035-001
- Research Site
-
-
-
-
-
Frankfurt am Main, Germany, 60590
- Research Site
-
-
-
-
-
Southampton, United Kingdom, SO16 6YD
- Research Site
-
-
-
-
California
-
Long Beach, California, United States, 90806
- Research Site
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Research Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Research Site
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83404
- Research Site
-
-
New York
-
Stony Brook, New York, United States, 11794
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Research Site
-
-
South Carolina
-
Mount Pleasant, South Carolina, United States, 29464
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant must be aged ≥ 29 weeks gestational age (GA) to < 18 years of age.
- Participant must weigh a minimum of 1.5 kg.
COHORT 1
- Increased risk of severe COVID-19 because of immunocompromised state or one or more comorbid conditions that increase the risk of severe COVID-19.
- Increased risk for SARS-CoV-2 infection.
- Medically stable (disease not requiring significant change in therapy or hospitalization for worsening disease during the one month prior to enrollment).
- A negative RT-PCR test collected ≤ 3 days prior to Day 1 or a negative rapid SARS-CoV-2 antigen test at screening.
- No COVID-19 symptoms prior to enrollment within 10 days of dosing.
- Increased risk for SARS-CoV-2 infection.
COHORT 2
- Increased risk of severe COVID-19 because of immunocompromised state or one or more comorbid conditions that increase the risk of severe COVID-19.
- Medically stable (disease not requiring significant change in therapy or hospitalization for worsening disease during the one month prior to enrollment).
- A positive RT-PCR test collected ≤ 3 days prior to Day 1 or a positive rapid SARS-CoV-2 antigen test at screening.
- Symptomatic participants must be dosed with IMP no more than 7 days from the self-reported date of first reported sign/symptom.
- Oxygenation saturation of ≥ 92% obtained at rest within 24 hours prior to Day 1 unless the potential participant regularly receives chronic supplementary oxygen for an underlying lung condition.
Note that Cohort 2 will only be included if the indication is progressed in adults.
COHORT 3
- Participants hospitalized with COVID-19 with a time between onset of symptoms and dosing AZD7442 of ≤ 7 days.
- A positive RT-PCR test collected ≤ 3 days before Day 1 or a positive rapid SARS-CoV-2 antigen test at screening.
- Spontaneous blood Alanine Aminotransferase (ALT)/Aspartate Transaminase (AST) levels ≤ 5 times the ULN.
- Glomerular Filtration Rate (GFR) ≥ 30 mL/min/1.73 m2.
Participants will receive IM AZD7442 unless they meet any of the following criteria for IV administration:
- The participant has severe COVID-19.
- Contraindication of intramuscular (IM) dose due to thrombocytopenia, coagulation defects or any other condition that would compromise the absorption of AZD7442 or safety of the participant.
- Physician considers IV the appropriate route.
Exclusion Criteria:
All Cohorts
- Cohort 1: Significant infection or other acute illnesses including fever on or the day prior to receiving AZD7442.
- History of SARS-CoV-1 or Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
- Cohorts 1 and 2: Current need for immediate medical attention or current need for hospitalization.
- Mechanical ventilation or extracorporeal membrane oxygenation requirement for COVID-19.
- History of allergic or reaction to any component of the study drug formulation.
- History of hypersensitivity, injection/infusion-relation reactions or severe adverse reactions following administration of a monoclonal antibody (mAb).
- Co-morbidity requiring surgery within 7 days prior to study entry or is deemed life-threatening within 30 days prior to study entry.
- Prior receipt of convalescent COVID-19 plasma/sera or hyperimmune globulin therapy.
- Prior receipt of mAb/biologic indicated for the prevention of SARS-CoV-2, treatment of COVID-19, or expected receipt during the period of study follow-up.
- Prior receipt of a COVID-19 vaccine ≤ 14 days before screening or plan to receive a COVID-19 vaccination ≤ 14 days after IMP administration at study Visit 1.
- History of alcohol or drug abuse within the past 2 years.
- Investigational Drugs or Devices: Treatment with investigational drug or device in another clinical trial within the last 30 days or 5 half-lives of the drug (whichever is longer) prior to screening. Note: Participation in observational studies (ie, studies that do not require medication, blood draws, or an additional intervention) is not exclusionary. Interventional trials which do not include investigational drugs (only include approved therapies), or investigational treatment regimens may be considered if the blood draw requirements and study interventions are minimal and not deemed by the Investigator to interfere with completion of the planned study sampling and follow-up.
- Vulnerable persons (eg, ward of the state, kept in detention).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AZD7442
All participants will receive a single dose of AZD7442 on Day 1, either IM (AZD8895 followed by AZD1061) or IV (AZD8895 + AZD1061 concurrently).
|
IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order. IV Administration: AZD7442 is dosed by co-administration of AZD8895 and AZD1061 in a single IV infusion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum concentrations of AZD7442
Time Frame: Day 1 to Day 366
|
The serum concentrations of AZD7442 after a single IM or IV dose in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
Maximum serum concentration (Cmax)
Time Frame: Day 1 to Day 366
|
The Cmax of AZD7442 after a single dose in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
Time to reach maximum serum concentration (tmax)
Time Frame: Day 1 to Day 366
|
The tmax of AZD7442 after a single dose in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
Terminal half-life (t1/2)
Time Frame: Day 1 to Day 366
|
The t1/2 of AZD7442 after a single dose in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
Area under the serum concentration versus time curve from time zero to time of last measurable concentration (AUC0-last)
Time Frame: Day 1 to Day 366
|
The AUC0-last of AZD7442 after a single dose in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
Area under the serum concentration versus time curve extrapolated to infinity (AUC0-inf)
Time Frame: Day 1 to Day 366
|
The AUC0-inf of AZD7442 after a single dose in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
Time to last measurable concentration (tlast)
Time Frame: Day 1 to Day 366
|
The tlast of AZD7442 after a single dose in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
Percentage of AUC0-inf extrapolated to infinity (% AUCex)
Time Frame: Day 1 to Day 366
|
The %AUCex of AZD7442 after a single dose in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
Apparent total clearance (CL/F)
Time Frame: Day 1 to Day 366
|
The CL/F of AZD7442 after a single dose in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
Apparent volume of distribution based on terminal phase (Vz/F)
Time Frame: Day 1 to Day 366
|
The Vz/F of AZD7442 after a single dose in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
Systemic clearance (CL)
Time Frame: Day 1 to Day 366
|
The CL of AZD7442 after a single dose in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
Volume of distribution at steady state (Vss)
Time Frame: Day 1 to Day 366
|
The Vss of AZD7442 after a single dose in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
Model-derived predicted serum AZD7442 concentrations
Time Frame: Day 1 to Day 366
|
The serum concentrations of AZD7442 after a single dose in pediatric participants will be model-derived.
|
Day 1 to Day 366
|
Model-derived predicted AUC0-inf
Time Frame: Day 1 to Day 366
|
The AUC0-inf of AZD7442 after a single dose in pediatric participants will be model-derived.
|
Day 1 to Day 366
|
Number of participants with adverse events (Treatment Emergent Adverse Events [TEAEs], Serious Adverse Events [SAEs], and Adverse Event of Special Interests [AESIs])
Time Frame: Day 1 to Day 457 (upto 15 months)
|
The safety and tolerability of AZD7442 after a single dose in pediatric participants will be evaluated.
|
Day 1 to Day 457 (upto 15 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All Cohorts (Other than Neonates) Titer of SARS-CoV-2 neutralizing antibodies (nAb)
Time Frame: Day 1 to Day 366
|
The PD of AZD7442 after a single dose in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
All Cohorts (Other than Neonates) - Number of participants with positive/negative antidrug antibodies (ADA) result and nAb to AZD7442.
Time Frame: Day 1 to Day 366
|
The immunogenicity profile of AZD7442 after a single dose in pediatric participants will be evaluated.
Number of participants with positive/negative ADA result and nAb to AZD7442 will be evaluated.
|
Day 1 to Day 366
|
Cohort 1 (Prophylaxis) - Incidence of SARS-CoV-2 infections
Time Frame: Day 1 to Day 366
|
The incidence of SARS-CoV-2 infections with or without COVID-19 symptoms after a single dose of AZD7442 in pediatric participants will be evaluated.
|
Day 1 to Day 366
|
Cohort 2 and Cohort 3 (Treatment) - Change from baseline to Day 8 in viral load
Time Frame: Baseline, Day 8
|
The SARS-CoV-2 viral loads measured by qRT-PCR after a single dose of AZD7442 in pediatric participants will be evaluated.
|
Baseline, Day 8
|
Cohort 2 and Cohort 3 (Treatment) - Proportion of participants with progression of COVID-19
Time Frame: Day 1 to Day 29
|
The percentage of participants with progression of COVID-19 after a single dose of AZD7442 in pediatric participants will be evaluated.
|
Day 1 to Day 29
|
Cohort 2 and Cohort 3 (Treatment) - The incidence of COVID-19-related death occurring after dosing with IMP through 90 days
Time Frame: Day 1 to Day 90
|
COVID-19-related death after a single dose of AZD7442 in pediatric participants will be evaluated.
|
Day 1 to Day 90
|
Cohort 3 (Severe COVID-19) - Time to sustained recovery
Time Frame: Day 1 to Day 366 (from the index hospitalization followed by being alive and home for 14 consecutive days)
|
The time to sustained recovery from severe COVID-19 after a single dose of AZD7442 in pediatric participants will be evaluated.
|
Day 1 to Day 366 (from the index hospitalization followed by being alive and home for 14 consecutive days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nasal concentrations of AZD7442 at specified time points during the study period when administered as a single IM or IV dose
Time Frame: Post Day 1 to Day 366
|
The concentration of AZD7442 in nasal fluid after a single dose in pediatric participants will be evaluated.
|
Post Day 1 to Day 366
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D8850C00006
- 2021-006056-13 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV-2
-
Argorna Pharmaceuticals Co., LTDCompleted
-
Argorna Pharmaceuticals Co., LTDCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Active, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
Arcturus Therapeutics, Inc.Terminated
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsCompleted
-
Centre Hospitalier Universitaire DijonUnknown
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionNot yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Not yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical CollegeActive, not recruiting
Clinical Trials on AZD7442
-
AstraZenecaCompletedHealthy Volunteer | Coronavirus Disease 2019 (COVID-19)China
-
AstraZenecaCompletedCoronavirus Disease 2019 (COVID-19)China
-
AstraZenecaParexelCompletedCOVID-19United Kingdom
-
University of Rome Tor VergataCompletedCOVID-19 Pandemic | Transplant-Related DisorderItaly
-
AstraZenecaIqvia Pty LtdActive, not recruitingCOVID-19United States, Belgium, France, Spain, United Kingdom
-
AstraZenecaNot yet recruitingCOVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
-
AstraZenecaTerminated
-
MediMergent, LLCTerminatedSARS-CoV-2 InfectionUnited States
-
AstraZenecaIqvia Pty LtdCompletedCOVID-19United States, United Kingdom